Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Change in Accured Expenses (2019 - 2025)

Benitec Biopharma's Change in Accured Expenses history spans 7 years, with the latest figure at -$159000.0 for Q1 2025.

  • For Q1 2025, Change in Accured Expenses fell 8050.0% year-over-year to -$159000.0; the TTM value through Mar 2025 reached -$91000.0, down 200.0%, while the annual FY2024 figure was $39000.0, 46.58% down from the prior year.
  • Change in Accured Expenses for Q1 2025 was -$159000.0 at Benitec Biopharma, down from $61000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $66000.0 in Q2 2021 and bottomed at -$159000.0 in Q1 2025.
  • The 5-year median for Change in Accured Expenses is $16000.0 (2024), against an average of $12117.6.
  • The largest annual shift saw Change in Accured Expenses surged 733.33% in 2023 before it tumbled 8050.0% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $3000.0 in 2021, then skyrocketed by 100.0% to $6000.0 in 2022, then soared by 733.33% to $50000.0 in 2023, then increased by 22.0% to $61000.0 in 2024, then tumbled by 360.66% to -$159000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Change in Accured Expenses are -$159000.0 (Q1 2025), $61000.0 (Q4 2024), and $16000.0 (Q3 2024).